window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 15, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

migraine

  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA grants De Novo authorisation to Avulux migraine light-sensitivity lens

    The FDA has granted De Novo marketing authorisation to Avulux, [...]

    August 24, 2026
  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Therapeutic Areas

    Theranica expands Nerivio migraine device coverage to more than half of insured Americans

    Theranica’s Nerivio wearable migraine therapy is now covered by health [...]

    July 13, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE backs AQUIPTA for acute migraine treatment in England and Wales

    The National Institute for Health and Care Excellence (NICE) has [...]

    June 9, 2026
  • Clinical & Regulatory,Digital & Data,Drug Delivery & Formulation,Therapeutic Areas

    Study confirms Nerivio REN wearable safe with continuous glucose monitoring devices

    A new study confirms that Theranica’s Nerivio REN wearable for [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Isomab data support safety of angiogenic approaches in coronary artery disease
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • FDA approves Tivicay PD for children with HIV weighing at least 2kg
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Tezspire meets Phase 3 endpoints in eosinophilic esophagitis
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top